This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read XOMA’s 8K filing here.
About XOMA
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
Featured Articles
- Five stocks we like better than XOMA
- What is a Secondary Public Offering? What Investors Need to Know
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- There Are Different Types of Stock To Invest In
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Differences Between Momentum Investing and Long Term Investing
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
